Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

BACKGROUND: The activity of palbociclib as a single agent in advanced breast cancer has not been extensively studied, with the only available clinical data limited to heavily pretreated patients. Preclinical data suggests palbociclib may partially reverse endocrine resistance, though this hypothesis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Malorni, L, Curigliano, G, Minisini, A M, Cinieri, S, Tondini, C A, D’Hollander, K, Arpino, G, Bernardo, A, Martignetti, A, Criscitiello, C, Puglisi, F, Pestrin, M, Sanna, G, Moretti, E, Risi, E, Biagioni, C, McCartney, A, Boni, L, Buyse, M, Migliaccio, I, Biganzoli, L, Di Leo, A
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6454527/
https://ncbi.nlm.nih.gov/pubmed/29893790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy214
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados